ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026 At the ASCO GU 2026 Conference, ImmVira showcased early results from a clinical trial of MVR-T3011 for BCG-naïve bladder cancer patients, signaling potential expansion in treatment options.

ImmVira Presents Promising MVR-T3011 Data for Bladder Cancer at ASCO GU 2026 #China #Suzhou #Bladder_Cancer #ImmVira #MVR-T3011

ImmVira Unveils Groundbreaking Data on MVR-EX105 for Targeted Fat Reduction ImmVira's MVR-EX105 shows promising results for fat reduction and muscle preservation, presented at the 2025 IFSO Congress, heralding a new era in non-invasive treatments.

ImmVira Unveils Groundbreaking Data on MVR-EX105 for Targeted Fat Reduction #China #Suzhou #biotechnology #ImmVira #MVR-EX105

ImmVira's Engineered Exosomes Set to Transform Aesthetic Medicine Landscape ImmVira Group's engineered exosome products have received INCI designation, promising innovative treatments for alopecia and localized fat reduction in the booming aging-related market.

ImmVira's Engineered Exosomes Set to Transform Aesthetic Medicine Landscape #ImmVira #EX104 #EX105

ImmVira Begins Phase II Trial of Oncolytic Therapy for Bladder Cancer ImmVira has launched its first patient dosing in a Phase II trial assessing MVR-T3011 for high-risk bladder cancer patients unresponsive to BCG treatment.

ImmVira Begins Phase II Trial of Oncolytic Therapy for Bladder Cancer #China #Suzhou #Bladder_Cancer #ImmVira #MVR-T3011

ImmVira Unveils Groundbreaking Engineered Exosomes for Cosmetic Applications ImmVira's latest engineered exosome, MVR-EX103, receives INCI approval, setting a new standard in cosmetic ingredients and targeting skin rejuvenation.

ImmVira Unveils Groundbreaking Engineered Exosomes for Cosmetic Applications #China #Suzhou #ImmVira #INCI #MVR-EX103